Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00510484 · ClinicalTrials.gov registry record · Phase 3
Study Investigating a Delayed-Release Pancrelipase in Patients With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis
A Phase 3 study, sponsored by Solvay Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 35
- Enrollment target
NCT00510484 is a Phase 3 study that has completed, run by Solvay Pharmaceuticals. The registered enrollment target is 35 participants.
The verdict
NCT00510484, a Phase 3 study, has completed, sponsored by Solvay Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 35 participants
- Enrollment target
Study Summary
This study will assess the effect of pancrelipase delayed release 24,000 unit capsules on fat and nitrogen absorption in subjects with PEI due to Cystic Fibrosis.
Interventions
- DRUG Placebo Comparator
- DRUG Pancrelipase Delayed Release
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2007-11 |
| Est. Completion | 2008-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00510484
The ClinicalTrials.gov registry entry for NCT00510484 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Solvay Pharmaceuticals, which has 35 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo Comparator is the first listed.
NCT00510484 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00510484 about?
NCT00510484 is a clinical study titled "Study Investigating a Delayed-Release Pancrelipase in Patients With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis". This study will assess the effect of pancrelipase delayed release 24,000 unit capsules on fat and nitrogen absorption in subjects with PEI due to Cystic Fibrosis.
What is the current status of trial NCT00510484?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 35 participants. The study started on 2007-11. Estimated completion is 2008-03.
What interventions are being tested in trial NCT00510484?
The interventions under investigation include: Placebo Comparator (DRUG), Pancrelipase Delayed Release (DRUG).
Who is sponsoring clinical trial NCT00510484?
This trial is sponsored by Solvay Pharmaceuticals, which has 35 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.